227 related articles for article (PubMed ID: 12504040)
1. Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems.
Denis F; Garaud P; Bardet E; Alfonsi M; Sire C; Germain T; Bergerot P; Rhein B; Tortochaux J; Oudinot P; Calais G
Int J Radiat Oncol Biol Phys; 2003 Jan; 55(1):93-8. PubMed ID: 12504040
[TBL] [Abstract][Full Text] [Related]
2. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma.
Denis F; Garaud P; Bardet E; Alfonsi M; Sire C; Germain T; Bergerot P; Rhein B; Tortochaux J; Calais G
J Clin Oncol; 2004 Jan; 22(1):69-76. PubMed ID: 14657228
[TBL] [Abstract][Full Text] [Related]
3. Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy--a multicenter randomized trial.
Olmi P; Crispino S; Fallai C; Torri V; Rossi F; Bolner A; Amichetti M; Signor M; Taino R; Squadrelli M; Colombo A; Ardizzoia A; Ponticelli P; Franchin G; Minatel E; Gobitti C; Atzeni G; Gava A; Flann M; Marsoni S
Int J Radiat Oncol Biol Phys; 2003 Jan; 55(1):78-92. PubMed ID: 12504039
[TBL] [Abstract][Full Text] [Related]
4. [T.i.d. accelerated radiotherapy alone or alternating with chemotherapy in patients with a locally advanced ORL cancer: analysis of late toxicity].
Laszlo A; Rosset A; Hermann F; Ozsahin M; Zouhair A; Mirimanoff RO
Cancer Radiother; 2001 Apr; 5(2):130-7. PubMed ID: 11355577
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma.
Calais G; Alfonsi M; Bardet E; Sire C; Germain T; Bergerot P; Rhein B; Tortochaux J; Oudinot P; Bertrand P
J Natl Cancer Inst; 1999 Dec; 91(24):2081-6. PubMed ID: 10601378
[TBL] [Abstract][Full Text] [Related]
6. Long-term results of conventional radiotherapy versus accelerated hyperfractionated radiotherapy versus concomitant radiotherapy and chemotherapy in locoregionally advanced carcinoma of the oropharynx.
Fallai C; Bolner A; Signor M; Gava A; Franchin G; Ponticelli P; Taino R; Rossi F; Ardizzoia A; Oggionni M; Crispino S; Olmi P
Tumori; 2006; 92(1):41-54. PubMed ID: 16683383
[TBL] [Abstract][Full Text] [Related]
7. [Stage III and IV cancers of the oropharynx: results of a randomized study of Gortec comparing radiotherapy alone with concomitant chemotherapy].
Calais G; Alfonsi M; Bardet E; Sire C; Germain T; Bergerot P; Rhein B; Tortochaux J; Oudinot P; Bertrand P
Bull Cancer; 2000 Aug; 87 Spec No():48-53. PubMed ID: 11082723
[TBL] [Abstract][Full Text] [Related]
8. [Conservative treatment of extremity soft tissue sarcomas. Functional evaluation using LENT-SOMA scales and Enneking scoring].
Tawfiq N; Lagarde P; Stöckle E; Thomas L; Bui BN; Kantor G
Cancer Radiother; 2000; 4(6):421-7. PubMed ID: 11191848
[TBL] [Abstract][Full Text] [Related]
9. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.
Staar S; Rudat V; Stuetzer H; Dietz A; Volling P; Schroeder M; Flentje M; Eckel HE; Mueller RP
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1161-71. PubMed ID: 11483325
[TBL] [Abstract][Full Text] [Related]
10. Increasing the rate of late toxicity by changing the score? A comparison of RTOG/EORTC and LENT/SOMA scores.
Hoeller U; Tribius S; Kuhlmey A; Grader K; Fehlauer F; Alberti W
Int J Radiat Oncol Biol Phys; 2003 Mar; 55(4):1013-8. PubMed ID: 12605981
[TBL] [Abstract][Full Text] [Related]
11. Comparing the RTOG/EORTC and LENT-SOMA scoring systems for the evaluation of late skin toxicity after
Mao MH; Zhang J; Zhang JG
Brachytherapy; 2017; 16(4):877-883. PubMed ID: 28495444
[TBL] [Abstract][Full Text] [Related]
12. [Concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conservative surgery enhances late toxicities].
Toledano A; Garaud P; Serin D; Fourquet A; Bosset JF; Miny-Buffet J; Favre A; Azria D; Body G; Le Floch O; Calais G
Cancer Radiother; 2006 Jun; 10(4):158-67. PubMed ID: 16632399
[TBL] [Abstract][Full Text] [Related]
13. Late radiation effects to the rectum and bladder in gynecologic cancer patients: the comparison of LENT/SOMA and RTOG/EORTC late-effects scoring systems.
Anacak Y; Yalman D; Ozsaran Z; Haydaroğlu A
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1107-12. PubMed ID: 11483319
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase I/II trial of two variants of accelerated fractionated radiotherapy regimens for advanced head and neck cancer: results of RTOG 88-09.
Fu KK; Clery M; Ang KK; Byhardt RW; Maor MH; Beitler JJ
Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):589-97. PubMed ID: 7790243
[TBL] [Abstract][Full Text] [Related]
15. French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC).
Bensadoun RJ; Bénézery K; Dassonville O; Magné N; Poissonnet G; Ramaïoli A; Lemanski C; Bourdin S; Tortochaux J; Peyrade F; Marcy PY; Chamorey E; Vallicioni J; Seng H; Alzieu C; Géry B; Chauvel P; Schneider M; Santini J; Demard F; Calais G
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):983-94. PubMed ID: 16376489
[TBL] [Abstract][Full Text] [Related]
16. Radiochemotherapy for anal carcinoma - effectivity and late toxicity.
Mai SK; Grieger J; Lachmann R; Bohrer M; Tiefenbacher U; Wenz F
Onkologie; 2002 Feb; 25(1):55-9. PubMed ID: 11893884
[TBL] [Abstract][Full Text] [Related]
17. Concomitant b.i.d. radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in unresectable squamous-cell carcinoma of the pharynx: clinical and pharmacological data of a French multicenter phase II study.
Bensadoun RJ; Etienne MC; Dassonville O; Chauvel P; Pivot X; Marcy PY; Prevost B; Coche-Dequeant B; Bourdin S; Vallicioni J; Poissonnet G; Courdi A; Teissier E; Lagrange JL; Thyss A; Santini J; Demard F; Schneider M; Milano G
Int J Radiat Oncol Biol Phys; 1998 Sep; 42(2):237-45. PubMed ID: 9788400
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer: long-term follow-up of RTOG 92-04.
Komaki R; Seiferheld W; Ettinger D; Lee JS; Movsas B; Sause W
Int J Radiat Oncol Biol Phys; 2002 Jul; 53(3):548-57. PubMed ID: 12062596
[TBL] [Abstract][Full Text] [Related]
19. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas.
Lee DJ; Cosmatos D; Marcial VA; Fu KK; Rotman M; Cooper JS; Ortiz HG; Beitler JJ; Abrams RA; Curran WJ
Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):567-76. PubMed ID: 7790241
[TBL] [Abstract][Full Text] [Related]
20. Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer: Radiation Therapy Oncology Group (RTOG) 92-04.
Komaki R; Scott C; Ettinger D; Lee JS; Fossella FV; Curran W; Evans RF; Rubin P; Byhardt RW
Int J Radiat Oncol Biol Phys; 1997 Apr; 38(1):149-55. PubMed ID: 9212017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
